

Maternal RSV programme for infant protection: introduction of a new immunisation programme. A webinar for health professionals

9th July 2024 14:30 - 15:45

Maternal programme for infant protection


- Welcome Dr Julie Yates (UKHSA)
- A clinical perspective Dr Tami Benzaken (UKHSA)
- Epidemiology, vaccination & safety Dr Conall Watson (UKHSA)
- Vaccine and supporting documentation for HCPs Greta Hayward (UKHSA)
- Programme delivery Caroline Temmink & Felipe Castrocardona (NHS England)
- Data recording and reporting James Spirit (NHS England)
- Resources and communications Cherstyn Hurley (UKHSA)
- Q&A



RSV disease in infants

Dr Tami Benzaken Paediatrician & UKHSA Fellow

RSV Disease





- RSV is a very common respiratory virus
- Spread through respiratory secretions
- At least half of children experience an RSV infection in 1st year of life and almost all by age of 2 years (Henderson et al 1979, Berbers et al 2021)
- Occurs year round, but primarily in October- March season
- Usually causes mild, self-limiting respiratory infection in adults and older children, but can be severe in infants causing bronchiolitis
- RSV responsible for ~ 80% of all bronchiolitis cases

Burden on Healthcare Services

- Each year in UK, RSV contributes to an estimated:
 - 450,000 GP attendances (Taylor et al)
 - 33,500 hospital admissions (Reeves)
- 5% of RSV-associated admissions were in high-risk infants, requiring 21% of the estimated bed days.

Age	RSV	Unspecified
Under 3 months	15,454 (46%)	20,747 (40%)
3 to 5 months	7,610 (23%)	13,718 (26%)
6 to 11 months	6,513 (19%)	13,593 (26%)
1 to 2 years	4,143 (12%)	3,960 (8%)
Total	33,720 (100%)	52,018 (100%)






Clinical Presentation: RSV Bronchiolitis

- RSV bronchiolitis occurs in children under 1 and most severely affects <3 months
- Causes inflammation of airways and breathing difficulties
- Signs & symptoms: cough, coryza, pyrexia, reduced feeding, increased work of breathing, hypoxia
- Symptoms worse on day 3-4 of illness
- High risk of severe disease: prematurity, chronic lung disease, congenital heart disease, immunodeficiency and other congenital anomalies
 - Currently targeted high-risk programme in place for this cohort (palivizumab) which will continue



Management







- Supportive treatment only:
 - Feeding support (nasogastric/ intravenous)
 - Breathing support (oxygen, noninvasive & invasive ventilation)
- Stories of parents:
 - <u>resc-eu.org/parents-</u> patients/rsv/stories-of-parents/
- <u>https://www.nhs.uk/conditions/bro</u> nchiolitis/



Morbidity & Mortality

- Complications: apnoeas, hypoxia, secondary bacterial infections.
- Possibly associated with viral wheeze and asthma in childhood
- Up to nearly 4% of those admitted with RSV bronchiolitis require PICU admission (risk increased with prematurity).
- 20-40 deaths in children from RSV every year in UK
 - high-risk infants hospitalised with RSV have 3% risk of death (Muller-Pebody et al 2002)
 - Significant social inequalities in RSV mortality



Conclusions



- RSV causes significant disease in infants and places considerable impact on NHS services over winter months
- It is a leading cause of infant mortality globally and last year contributed to 34 child deaths in England
- A universal maternal vaccine will offer protection to infants from RSV bronchiolitis improving clinical outcomes for these children as well as reducing the burden on healthcare services





RSV public health perspective: from surveillance to immunisation

Conall Watson MPharm PhD FFPH Consultant Epidemiologist Immunisation and Vaccine-preventable Diseases Division

RSV surveillance

- UKHSA monitors RSV activity in England through the season - published at gov.uk/government/collections/weekly-national-flu-reports
- RSV surveillance is also used to inform immunisation policy, such as JCVI advice.
- UKHSA will be monitoring the impact, equity and effectiveness of the RSV immunisation programme and supporting MHRA with safety monitoring.





RSV prevention

- Respiratory transmission precautions
 - o sneezing/coughing into bend of the elbow
 - Handwashing with soap
 - It's OK to ask people with colds not to visit small babies
 - But key transmitters may be siblings, or parents who cannot avoid contact
- Reducing the risk of/from severe disease
 - Not smoking around babies / avoid indoor environmental smoke
 - Advice on when to seek care
- Immunisation





New RSV immunisations for infant protection by passive immunisation




Nirsevimab (Beyfortus®) infant monoclonal antibody immunisation, developed by Sanofi/AstraZeneca


Abrysvo® Pre-F RSV antenatal vaccine, developed by Pfizer



JCVI assesses a wide range of evidence, including safety, efficacy over time, operational aspects and impact

Modelling of the **impact and cost effectiveness of potential immunisation strategies** was undertaken by the London School of Hygiene and Tropical Medicine to inform JCVI's advice





JCVI advice

"JCVI recognises that there is a **significant burden of RSV illness** in the UK population and **unmet public health need** which has a **considerable impact on NHS services** during the winter months.


JCVI advises that **both products are suitable for a universal programme to protect neonates and infants from RSV**.

JCVI **does not have a preference for either product** or whether a maternal vaccination or a passive immunisation programme should be the programme chosen to protect neonates and infants...


JCVI advises a preference for a year-round offer ... to ensure high uptake and for reasons of operational effectiveness because this would be less complex and resource intensive to deliver, compared with running seasonal campaigns."

Acceptability of RSV immunisations: UKHSA survey of 1061 pregnant women and new mums

How important is it to protect against RSV? (after reading an information sheet) (after ding an information sheet) (after reading after reading an information How likely would you be to accept...



Protection of infants by maternal vaccination




Severe RSV-Associated Lower Respiratory Tract Illness

Kampmann *et al*, 2023, MATISSE trial, *New Eng J Med* 10.1056/NEJMoa2216480

Vaccination from week 28 to birth

Ideally in week 28 or within a few weeks of this, so there is time for antibody production and transfer across the placenta, even if baby is born early.

Posthoc analysis of protection to 180 days age against severe RSV LRTI



See Munjal et al, RSVVW 2024, resvinet.org/conferences/rsvvw24/

The most commonly reported adverse reactions following immunisation were:

- vaccination site pain (41%)
- headache (31%)
- Myalgia (muscle ache) (27%)

Most reactions were mild and resolved within a few days.

Vaccine safety

Approved by MHRA based on quality, safety and efficacy:

"There are no major safety concerns" [1]

Median birth weight and median gestational week at birth were equal in vaccine and placebo groups in the phase 3 trial. [2]

No safety signals in operational use in the USA, where it has been given to over 100,000 women. [3]

Top 10 most common adverse events within a month of vaccination in the phase 3 trial

All statistically overlapping with placebo

	Percentage with event		
Adverse event	Vaccine (n=3682)	Placebo (n=3675)	
Premature delivery	2.1%	1.9%	
Pre-eclampsia	1.0%	0.9%	
Gestational hypertension	0.8%	0.6%	
SARS-CoV-2	0.6%	0.6%	
UTI	0.6%	0.5%	
Gestational diabetes	0.6%	0.4%	
Anaemia	0.4%	0.6%	
Premature labour	0.4%	0.3%	
Threatened labour	0.4%	0.3%	
Prem rupture of membranes	0.3%	0.2%	

[1] MHRA Public Assessment Report PLGB 00057/1722. [2] Kampmann, Radley & Munjal 2023, *New Eng J Med* 10.1056/NEJMc2307729

[3] ACIP, June 2024

Co-administration of RSV vaccine with other routine vaccines and immunoglobulins in pregnancy

Product	Can be co-administered with RSV vaccine in pregnancy?
Influenza vaccine	Yes
COVID-19 vaccine	Yes
Pertussis-containing vaccine	Yes*
Anti-D immunoglobulin	Yes

*A phase 2 study showed reduced immune response to some pertussis components when a DTaP vaccine was coadministered with an RSV vaccine in non-pregnant women age 18-49 years. [1]

- The clinical impact of this is unknown, but likely to be small.
- If the pertussis-containing vaccine is given at the typical time (around week 20) and RSV vaccine at the scheduled time (week 28 onward), there is no chance of a reduced pertussis response.
- If a woman has not had her antenatal pertussis-containing vaccine by the time she is attending for RSV vaccine, give both at once to maximise timely antibody production.

Subsequent pregnancies

For best protection of the baby **vaccinate in every pregnancy** from week 28, regardless of the interval between pregnancies.



CC BY-NC-SA 2.0 Walter Parenteau flickr.com/photos/51125929@N00

Monoclonal immunisation of higher-risk babies

Existing programme for immunisation of (very) high-risk babies continues:

- JCVI in Feb 2023 recommended that nirsevimab replace palivizumab for the currently eligible cohort because of its extended half-life and high efficacy, if it can be obtained by NHS Specialised Commissioning at an equivalent price.
- Palivizumab (Synagis®, AstraZeneca) is expected to continue to be the product in 2024-25 season, given IM monthly in paediatrics.

Ongoing area of policy development.

Box 1

High Risk due to chronic lung disease of prematurity (CLD), also known as bronchopulmonary dysplasia (BPD)

Pre-term infants who have moderate or severe CLD. Moderate or severe CLD is defined as 'preterm infants with compatible x-ray changes who continue to receive supplemental oxygen or respiratory support at 36 weeks post-menstrual age'.¹ Children who fall into the light and dark red shaded area of Table 1 should be offered prophylaxis

Infants with respiratory diseases who are not necessarily pre-term but who remain in oxygen at the start of the RSV season are also considered to be at higher risk

These infants may include those with conditions including:

- pulmonary hypoplasia due to congenital diaphragmatic hernia
- other congenital lung abnormalities (sometimes also involving congenital heart disease or lung malformation)
- interstitial lung disease

and including those receiving long term ventilation (LTV) at the onset of the season.^2 $\,$

High Risk due to Congenital Heart Disease (CHD)

Preterm infants with haemodynamically significant, acyanotic CHD at the chronological ages at the start of the RSV season and gestational ages at birth covered within the light red shaded area in Table 1.

Cyanotic or acyanotic CHD plus significant co-morbidities particularly if multiple organ systems are involved.

High Risk due to Severe Combined Immunodeficiency Syndrome (SCID)

Children less than 24 months of age with SCID – the most severe form of inherited deficiency of immunity, who are unable to mount either T-cell responses or produce antibody against infectious agents – until immune reconstituted.

Where clinical judgement of other individual patient circumstances strongly suggests that prophylaxis would prevent serious RSV infection in infants who are at particular risk of complications from RSV, use of nirsevimab (first-line, if available) or palivizumab could be considered during the RSV season.

		0	Sestational	age at birth	n (weeks+day	5)	
Chronological age (months)	≤24+0	24+1 to 26+0	26+1 to 28+0	28+1 to 30+0	30+1 to 32+0	32+1 to 34+0	≥34+1
<1.5							
1.5 to <3							
3 to <6							
6 to <9							
9							

1 Light red shaded area denotes eligibility for premature infants with haemodynamically significant acynanotic congenital heart disease; light or dark red areas denote eligibility for preterm infants with chronic lung disease. See text for further details including eligibility for other conditions.



The Respiratory Syncytial Virus (RSV) vaccine and healthcare practitioner documentation

Greta Hayward RGN, RM, MPH Consultant Midwife – Immunisation & Public Health Programmes Design, Implementation and Clinical Guidance Division

RSV vaccination of pregnant women eligibility criteria

Inclusion

- all pregnant women from 28 weeks' gestation
- eligible up until delivery (licensed 28-36 week)
- off label after week 36 of pregnancy in line with national recommendations
- single dose
- every pregnancy
- year-round programme

Exclusion

less than 28 weeks pregnant

Abrysvo® Pre-F RSV vaccine

- a non-live bivalent recombinant vaccine
- manufactured by Pfizer
- does not contain animal products
- full list of vaccine components and excipients in the Abrysvo® <u>Summary of product</u> <u>characteristics (SPC)</u>
- black triangle label
- POM PGD



Vaccine ordering

Ordering

- via the ImmForm website
- should be ordered regularly throughout the year
- the same Abrysvo® vaccine will be used for both the older adult and the vaccination of pregnant women programmes. They will be listed as separate items on ImmForm and the vaccine allocated for each programme should be ordered and managed independently where possible.

Vaccine preparation

- Each pack of Abrysvo® RSV vaccine contains:
- powder for 1 dose in a vial
- solvent (water for injection)
- vial adaptor
- 25G 25mm needle (suitable alternatives can be used if required)

Manufacturer's instructional video for storage and preparation of the administration of Abrysvo



Healthcare practitioner resources

All UKHSA healthcare practitioner resources relating to RSV vaccination for older adults will be available in the <u>UKHSA RSV immunisation programme collection</u>.

- the Green Book: Immunisation against infectious disease: <u>RSV Green Book</u> <u>chapter (27a)</u>
- Information for healthcare practitioner's guidance
- Training slide set
- Patient Group Direction (PGD): <u>RSV vaccine</u>
- Pfizer Abrysvo® vaccine preparation instructional video
- Pfizer Abrysvo® <u>Summary of product characteristics</u>

RSV immunisation programme for infants: Programme Delivery

Caroline Temmink and Felipe Castrocardona



Background: what is NHS England's role in the delivery of the RSV immunisation programme?

- NHS England leads the NHS in England to deliver high quality equitable services for all.
- NHS England regional teams are responsible for working with Integrated Care Boards (ICBs) to commission and pay providers to deliver the RSV immunisation programme.
- Delivery models and provider roles and responsibilities are determined by NHSE regional commissioning teams and their partner ICBs.
- To support delivery of the RSV immunisation programme, NHS England has developed commissioning guidance, clinical guardrails and national service schedules 2, 4 and 6.
- NHS England are working with UKHSA and DHSC to launch a public facing communications campaign to encourage uptake of the RSV vaccination amongst eligible groups.

Programme Delivery Model:

All women who are at least 28 weeks pregnant. After 28 weeks' gestation, pregnant women will remain eligible for the RSV vaccine up to birth. Providers are expected to deliver the RSV vaccination programme from 1 st September 2024. Providers should have provisions in place to offer the vaccine to pregnant women who have passed 28 weeks at that point.
The RSV vaccine should be offered to eligible pregnant women all year round from 28 weeks. RSV vaccination discussion is encouraged at any point in the antenatal period prior to the point of offer. Midwives and healthcare professionals should use antenatal contacts as early as possible for vaccination discussion.
Most vaccinations will be delivered by commissioned trust providers including community providers in a small number of areas. In some areas other supporting immunisation services may also be commissioned to offer in reach and outreach services. RSV vaccinations should be administered by trained staff operating under an appropriate legal mechanism. A template PGD will be available for local approval from the week commencing 5 th August 2024, which will allow specified registered health care professionals to vaccinate.
General practice provision will be commissioned through the GP contract as a component of Essential Services, to proactively offer and provide RSV vaccination in pregnancy on an opportunistic or on request basis from 28 weeks of pregnancy. Opportunistic offer should proactively be made when the women attends the practice where records indicate vaccination status remains incomplete. The Statement of Financial Entitlements (SFE) will be updated in due course to include RSV vaccination in pregnancy at the standard item of service fee. Practices will be required to manually claim through CQRS for RSV vaccinations in pregnancy as an automated service will not be in place for the start of the programme.

Programme Delivery Model:

Who will be responsible for inviting eligible people for their RSV vaccine?	Local services must ensure that all pregnant women are informed of their eligibility, are proactively offered and recalled and where accepted provided vaccination, as part of routine care.
Who will be responsible for booking vaccination appointments?	Local services must ensure that all eligible pregnant women who request an RSV vaccination are offered an appointment.
How will supply of the RSV	Providers should order Abrysvo® online via the ImmForm website.
vaccine be managed?	Abrysvo® will be available to order from 1st August 2024 and providers will be able to monitor their orders and deliveries through ImmForm.
	It is recommended that providers order no more than 2 weeks' worth of stock.
Can the RSV vaccine be co-	Pregnant women:
administered with other vaccines?	Abrysvo® should not be routinely scheduled with other vaccinations in pregnancy.
	Pregnant women can have Abrysvo® co-administered with inactivated influenza vaccine, COVID-19 vaccine and/or anti-D immunoglobulin, if necessary. When more than one vaccine is administered, it should be at different sites, preferably different limbs.
	If a pertussis containing vaccine has not been given by the time of attendance for Abrysvo® RSV vaccine, both vaccines can and should be given at the same appointment to ensure prompt development of immune response.

Roles and responsibilities

Providers (commissioned providers with maternity services, immunisation providers and general practice) are responsible for:

- Ensuring that they have read the information for Healthcare Practitioners document and the RSV training slide set.
- Ensuring that the template PGDs is approved before 1st September 2024 (General practice PGD approval is through routine processes).
- Ensuring staff are trained and competent to administer RSV vaccinations.
- Identifying pregnant women and informing them of their eligibility for the RSV vaccine, advocating uptake and ensuring they are up to date with all other vaccines they are eligible for. This includes signposting them to relevant NHS resources such as the patient information leaflet. The general practice offer is on request or opportunistic.
- Ordering vaccines via the ImmForm website. Providers should ensure that there is an ImmForm account set up for their organisation.
- Ensuring equality of access so that all eligible pregnant women who request an RSV vaccination are offered an appointment. Appointments should be
 delivered in a suitable and appropriate location. Vaccinations clinics/services commissioned from providers with maternity and immunisation services
 should ideally be set up within or as close as possible to antenatal maternity settings, to maximise convenience and uptake alongside routine maternity
 care.
- Administering RSV vaccinations.
- Ensuring vaccination events are recorded using nationally agreed applications. Vaccinations provided in a GP setting should be recorded directly onto GPIT systems. Vaccinations provided in a maternity setting should be recorded on the new NHS Record a Vaccination Service (RAVs) system.
- More information about the programme delivery model and provider roles and responsibilities will be outlined in the national RSV immunisation service schedules.

Midwives and Obstetricians. Roles and responsibilities, RSV programme

Trusted clinical experts and women's health champions: Promoting health and preventing disease

Midwives

Vaccine counselling and signposting: Immunisations education and advocacy within the maternity pathway, including the RSV vaccine.

- Vaccine administration: Registered healthcare professionals that can vaccinate include nurses, midwives and others. Who
 administers the vaccine is subject to local commissioning agreements. These agreements would include how Trusts and ICBs
 are supporting rollout, and should ensure it does not impact on safe staffing for core maternity care.
- Responsibilities: Provide evidence-based information about the importance of immunisations in pregnancy for both the woman
 and her unborn baby, in line with relevant guidelines (<u>NMC 2019</u>, <u>NICE 2021</u>, <u>HEE 2023</u>)
- Recommendation: Use the booking appointment to offer and discuss the RSV vaccine, as part of the *staying healthy during pregnancy* discussion (immunisations, lifestyle choices, etc.)

Obstetricians

- Vaccine counselling and signposting: Support Immunisations education and advocacy within the maternity pathway, including the RSV vaccine.
- Responsibilities: Take an active role in implementing public health priorities. Be knowledgeable about the current recommended vaccinations available to protect women and their unborn children, and provide balanced counselling (<u>NICE 2021</u>, <u>RCOG 2022</u>)
- Recommendation: Support implementation by checking if the pregnant woman has been offered and accepted RSV vaccination in this pregnancy, and if they have not, offer it.



UKHSA maternal programme webinar

Data recording and reporting

James Spirit

37 Vaccinations Digital Services

Recording RSV vaccination events

General practice providers:

RSV vaccinations given by general practice must be recorded directly onto GPIT systems.

Maternity service providers:


RSV vaccinations given by maternity service providers must be recorded on the new Record a Vaccination Service (RAVS) system.

RAVS is owned by NHS England and will be provided free of charge.

RAVS has been designed to help clinical staff record RSV vaccination events easily and effectively.

Recording vaccination events in RAVS will ensure GPs have an accurate record of vaccinations for their patients and will enable NHSE, UKHSA and MHRA to monitor the delivery, safety and efficacy of the RSV maternal programme for infant protection.

okta	End a patient Settings Beta This is a new service - your feedback (opens in a new tab) will help us to improve it.	Find a patient Settings Rota This is a new service - your fordback (one is is a new tab) will help us to improve it
Imail Password Image: Signed in	Detail The is a new service - your medicate, (opens in a new tab) will nep us to improve it. Automatic and the provided and the	Beta This is a new service - your feedback (opens in a new tab) will help us to improve it. Find a patient By NHS number By demographics By local records Search by NHS number Image: Search search search search search search search Search search search search search search search search search search search search search Search Search Search s





Respiratory Syncytial Virus maternal vaccination programme publications

July 9 2024 UKHSA Communications and Immunisation – Design, Implementation and Clinical guidance depts.

Respiratory Syncytial Virus Programme Letter

From 1 September 2024, a vaccination for Respiratory Syncytial Virus (RSV) will be available for:

- 1. Older adults aged 75 to 79
- Pregnant women who are at least 28 weeks pregnant

More details can be found on the <u>RSV</u> <u>programme letter</u> on GOV.UK.

Correspondence

Introduction of new NHS vaccination programmes against respiratory syncytial virus (RSV)

Applies to England

Contents	24 June 2024
Programme for older adults aged 75 to 79 years old	То:
Programme for pregnant women to protect infants	Trust:
Annexe A. Detailed information and guidance for healthcare professionals – Older adult programme	chief executiveschief operating officersmedical directors
Annexe B. Detailed information and guidance for healthcare professionals – pregnancy vaccination for infant protection programme	 chief pharmacist chief nurses head of midwifery
Annexe C. Detailed information and guidance for healthcare professionals – both programmes	Integrated Care Boards (ICB):
	 chief executives chief operating officers

RSV Collection on GOV.UK

The <u>RSV Collection</u> holds a range of information on the programme for the public and professionals.

This includes the following documents:

- 1. RSV Vaccination Programme Letter
- 2. JCVI advice on a RSV vaccination programme
- 3. RSV for older adults leaflet and poster
- 4. RSV for pregnant women leaflet and poster

Respiratory syncytial virus (RSV) is an enveloped RNA virus, in the same family as the human parainfluenza viruses and mumps and measles viruses. RSV is one of the common viruses that cause coughs and colds in winter. RSV is transmitted by large droplets and by secretions from contact with an infected person.

Infants under one year of age and the elderly are at the greatest risk of developing severe disease. While most RSV infections usually cause mild illness, infants aged less than 6 months frequently develop the most severe disease such as bronchiolitis and pneumonia, which may result in hospitalisation.

From 1 September 2024, 2 new respiratory syncytial virus (RSV) vaccination programmes will be introduced:

Programme for older adults aged 75 to 79 years old

All adults turning 75 years old on or after 1 September 2024 will be eligible for the routine programme and should be offered a single dose of the RSV vaccine. A one-off catch-up campaign for those already aged 75 to 79 years old on 1 September 2024 will be undertaken at the earliest opportunity.

Programme for pregnant women to protect infants

All women who are at least 28 weeks pregnant (the eligible cohort) on 1 September 2024, will be offered a single dose of the RSV vaccine. After that, pregnant women will become eligible as they reach 28 weeks gestation and remain eligible up to birth.

Programme documents

 Respiratory syncytial virus (RSV) vaccination programmes letter

 24 June 2024
 Correspondence

RSV immunisation programme: JCVI advice, 7 June 2023 (updated 11 September 2023) 11 September 2023 Independent report



RSV Vaccination Programme Launch Communications Plan

The programme

DHSC will announce two new routine RSV vaccination programmes

1. Maternal vaccine to protect infants

2. Older adults turning 75, alongside a catch-up programme for 75–79-year-olds.

- The vaccination programme will commence from September 2024
- The offer will be all-year-round (not seasonal)
- The offer is a one-off offer for adults. For pregnant women it is offered in every pregnancy.
- Delivery model: Older adults from GPs & some community pharmacies. Maternal is through commissioned services.

Objectives and audiences

- 1. Raise awareness among key audiences about the programmes:
 - Expectant mothers & wider family
 - Older adults & wider family
 - Healthcare professionals (GPs and Imms professionals)
 - Key stakeholders including RCPCH, RC Midwives, RC Nursing, RCGPs, Health Visitors, Maternity Action & Age UK
- 2. Encourage high uptake of the RSV vaccine in eligible populations
- 3. Maintain credibility of new vaccine and reassure audiences and stakeholders about safety
- 4. Ensure clear messaging for expectant mothers on how the new vaccine is scheduled into the existing maternal vaccine programme.

Key Messages (Note these will be refined for different audiences)

Maternal:


- From September 2024, pregnant women can have a vaccine to help protect their babies against RSV (Respiratory Syncytial Virus)
- You should be offered your vaccine around the time of your 28-week antenatal appointment
- Studies have shown the RSV vaccine is very safe for you and your baby
- A vaccine is needed in every pregnancy to give your new baby the best protection

Older Adults:

- A single dose of vaccine will help to boost protection as you reach an age group at highest risk of serious RSV infection.
- Everyone turning 75 years old on or after the 1 September 2024 will be offered a single dose of RSV vaccine.
- For the first year of the programme, the vaccine will also be offered to those who are already aged 75 to 79 years on 1 September 2024.
- RSV vaccine is given all year round

How to protect your baby from RSV

- This guide to the RSV vaccination for pregnant women contains the rationale for the programme, who is eligible and when they should have their RSV vaccine, safety and effectiveness, where to get more information and the symptoms of RSV.
- This leaflet can be ordered using product code: C24RSV03EN



From September 2024, pregnant women can have a free vaccine in each pregnancy, to protect their babies against Respiratory Syncytial Virus (RSV).

Protect your baby from RSV poster

Product Code: C24RSV03EN

There is a poster to promote the programme to pregnant women.

This should be displayed in GP surgeries, maternity units or midwifery settings and hospitals.



Speak to your midwife, maternity service or GP practice about your RSV appointment today.

Orown copyright 2024. Product code: FISVPOEN. tp.10K JULY 2024 (APS). UK Health Security Agency gateway number: 2024 If you want to order more copies of this poster, please visit: healthpublications.gov.uk or cell 0300-123 1002.

RSV Leaflet for Pregnant Women – translations and accessible versions currently being produced

Translations of the leaflet will be available to order and download in: Albanian, Arabic, Bengali, Bulgarian, Chinese (simplified), Chinese (traditional), Dari, Estonian, Farsi, French, Greek, Gujarati, Hindi, Italian, Latvian, Lithuanian, Nepali, Panjabi, Pashto, Polish, Portuguese, Romanian, Romany, Russian, Somali, Spanish, Tagalog, Tigrinya, Turkish, Twi, Ukrainian, Urdu, Yiddish and Yoruba. The poster and leaflets will also be available in a range accessible formats:

- 1. BSL video (product code: C24RSV03BSL)
- 2. Large print (product code: C24RSV03LP)
- 3. Audio (product code: C24RSV03AU)
- 4. Braille (product code: C24RSV03BR

Training and guidance slide set and health professional guidance, Green book chapter, will be published shortly.

PGD will be published later and be available to download in advance of the start of the programme.

Where to find the RSV publications to order – free service for all settings including those vaccinating



About this site

On this website you can order and download publications created by The Department for Health and Social Car Health Security Agency (UKHSA)

The Green Book has the latest information on vaccines and vaccination procedures, for vaccine preventable inf newsletter that features all our new publications, Green Book chapter updates and the latest developments in view past issues here and register to receive the newsletter

Health publications

website

Free service Deliveries 3-5 working days

Short link:

Health Publications




Resources to support health professionals delivering the routine vaccinations and looking after pregnant women

https://grco.de/healthpubs



Have you registered for Vaccine Update – Immunisation bulletin – RSV special issue coming soon



CQC endorsed – 'registering and reading Vaccine update is one of the indicators of best practice' <u>https://www.gov.uk/government/collections/vaccin</u> <u>e-update</u>

Audience:

Screening and immunisation teams, clinics, GP practices, practice nurses, midwives, student nurses, health professionals and anyone with an interest in the UK vaccination programmes.

One stop shop for policy, supply or vaccine programme implementation including the training, guidance documents, examples of best practice, implementation guidance and patient facing resources to promote the campaign.

Register for the free bulletin here: <u>Sign up to</u> receive the Vaccine update newsletter.



Order stocks of all of the resources on Health Publications website <u>https://www.healthpublications.gov.uk/Home.html</u> or phone 0300 123 1002

Reference Guide



